Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential thrombocythemia

  • Hongxing Liu
  • Chunrong Tong
  • Peng Cai
  • Jiangying Gu
  • Yuehui Lin
  • Ying Zhang
  • Wen Teng
  • He Wang
  • Ping Zhu
Research Article


Single-tube bi-directional allele specific amplification (SB-ASA) and real-time quantitative polymerase chain reaction (RQ-PCR) assays were developed and performed for JAK2V617F detection on 40 polycythemia vera (PV) samples, 31 essential thrombocythemia (ET) samples, 40 acute leukemia samples, and 40 healthy control samples. Differences between detect limitations of the two assays and their influence on the mutation detection rate were analyzed. The results showed that in some samples, the JAK2V617F burden was as low as nearly 1%, and thus more JAK2V617F-positive samples were detected by RQ-PCR than by SB-ASA assay due to the former higher detect limitation. Mutation allele ratios in PV and ET samples and their relevance to biological characteristics were also analyzed. The results showed that the mutation allele ratio was 0.436 ± 0.261 in PV, higher than the 0.216 ± 0.207 in ET; percentage of certainly homozygous mutation carriers in PV was 40.54%, higher than the 10% in ET. However, statistical analysis showed no relevance between mutation allele burden and sex or age. Our result shows that the pathogenesis of PV and ET may be related to the mutation allele burden of JAK2V617F.


JAK2V617F mutation real-time quantitative polymerase chain reaction polycythemia vera essential thrombocythemia 


  1. 1.
    James C, Ugo V, Le Couédic J P, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval J L, Constantinescu S N, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434(7037): 1144–1148PubMedCrossRefGoogle Scholar
  2. 2.
    Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz S B, Zhao Z J. Identification of an Acquired JAK2 Mutation in Polycythemia Vera. J Biol Chem, 2005, 280(24): 22788–22792PubMedCrossRefGoogle Scholar
  3. 3.
    Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, Vassiliou G S, Bench A J, Boyd E M, Curtin N, Scott M A, Erber W N, Green A R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464): 1054–1061PubMedGoogle Scholar
  4. 4.
    Lacout C, Pisani D F, Tulliez M, Gachelin F M, Vainchenker W, Villeval J L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, 2006, 108(5): 1652–1660PubMedCrossRefGoogle Scholar
  5. 5.
    Wernig G, Mercher T, Okabe R, Levine R L, Lee B H, Gilliland D G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 2006, 107(11): 4274–4281PubMedCrossRefGoogle Scholar
  6. 6.
    Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood, 2007, 109(12): 5104–5111PubMedCrossRefGoogle Scholar
  7. 7.
    Vannucchi A M, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20(6): 1055–1060PubMedCrossRefGoogle Scholar
  8. 8.
    Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, Ugo V, Saulnier P, Koscielny S, Le Couédic J P, Casadevall N, Vainchenker W, Delhommeau F. The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood, 2007, 110(3): 1013–1021PubMedCrossRefGoogle Scholar
  9. 9.
    Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi A M. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19(10): 1847–1849PubMedCrossRefGoogle Scholar
  10. 10.
    Pemmaraju N, Moliterno A R, Williams D M, Rogers O, Spivak J L. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia, 2007, 21(10): 2210–2212PubMedCrossRefGoogle Scholar
  11. 11.
    Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100(7): 2292–2302PubMedCrossRefGoogle Scholar
  12. 12.
    Levine R L, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland D G, Busque L. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET andMMM patients with clonal hematopoiesis. Blood. 2006, 107(10): 4139–4141PubMedCrossRefGoogle Scholar
  13. 13.
    Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda R C, Hermouet S. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood, 2006, 108(6): 1865–1867PubMedCrossRefGoogle Scholar
  14. 14.
    McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia, 2006, 20(1): 68–171CrossRefGoogle Scholar
  15. 15.
    Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J, Boggon T J, Wlodarska I, Clark J J, Moore S, Adelsperger J, Koo S, Lee J C, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa R A, Tefferi A, Griffin J D, Eck M J, Sellers W R, Meyerson M, Golub T R, Lee S J, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7(4): 387–397PubMedCrossRefGoogle Scholar
  16. 16.
    Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R, Tichelli A, Cazzola M, Skoda R C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, 352(17): 1779–1790PubMedCrossRefGoogle Scholar
  17. 17.
    Murugesan G, Aboudola S, Szpurka H, Verbic M A, Maciejewski J P, Tubbs R R, Hsi E D. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol, 2006, 125(4): 625–633PubMedGoogle Scholar
  18. 18.
    Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica, 2007, 92(1): 135–136PubMedCrossRefGoogle Scholar
  19. 19.
    Frohling S, Lipka D B, Kayser S, Scholl C, Schlenk R F, Dohner H, Gilliland D G, Levine R L, Dohner K. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood, 2006, 107(3): 1242–1243PubMedCrossRefGoogle Scholar
  20. 20.
    Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L, Gilliland D G, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood, 2005, 106(4): 1207–1209PubMedCrossRefGoogle Scholar
  21. 21.
    Patel R K, Lea N C, Heneghan M A, Westwood N B, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gaken J, Wendon J, Heaton N D, Mufti G J. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 2006, 130(7): 2031–2038PubMedCrossRefGoogle Scholar
  22. 22.
    Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannucci P M. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44(6): 1528–1534PubMedCrossRefGoogle Scholar
  23. 23.
    Scott L M, Scott M A, Campbell P J, Green A R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood, 2006, 108(7): 2435–2437PubMedCrossRefGoogle Scholar
  24. 24.
    Campbell P J, Scott L M, Buck G, Wheatley K, East C L, Marsden J T, Duffy A, Boyd E M, Bench A J, Scott M A, Vassiliou G S, Milligan D W, Smith S R, Erber W N, Bareford D, Wilkins B S, Reilly J T, Harrison C N, Green A R. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 2005, 366(9501): 1945–1953PubMedCrossRefGoogle Scholar
  25. 25.
    Tefferi A, Pardanani A. Evaluation of “increased” hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc, 2007, 82(5): 599–604PubMedCrossRefGoogle Scholar
  26. 26.
    James C, Delhommeau F, Marzac C, Teyssandier I, Couédic J P, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, Tulliez M, Vainchenker W, Ugo V, Casadevall N. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia, 2006, 20(2): 350–353PubMedCrossRefGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag GmbH 2008

Authors and Affiliations

  • Hongxing Liu
    • 1
  • Chunrong Tong
    • 1
  • Peng Cai
    • 1
  • Jiangying Gu
    • 1
  • Yuehui Lin
    • 1
  • Ying Zhang
    • 2
  • Wen Teng
    • 1
  • He Wang
    • 1
  • Ping Zhu
    • 2
  1. 1.Molecular Diagnosis CenterDaopei HospitalBeijingChina
  2. 2.Hematology LaboratoryPeking University First HospitalBeijingChina

Personalised recommendations